Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 1—January 2003

Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 5

Risk factors for infection or colonization with fluoroquinolone-resistant Streptococcus pneumoniaea

Factor Case patients
(n=27) Control
 patients
(n=54) Odds ratio
(95% CI) p value
Age (yr)b
72.5
(62.3–78.3)
75 (70–85)

0.01
Nursing home residence
14 (52%)
7 (13%)
7.2 (2.4 to 21.6)
<>
COPD
17 (63%)c
12 (22%)
5.9 (2.2 to 16.3)
0.001
Nosocomial
origin
18 (66%)
14 (26%)
5.7 (2.1 to 15.6)
0.001
Interval from day of admission to isolation of LRSP (days)b
7 (1–20)
1 (1–3)
-
<>
No. of prior
admissionsb
4 (2–7)
1 (0–3)
-
<>
Recent hospitalization
16 (59%)
13 (24%)
4.6 (1.7 to 12.3)
0.003
Multiple hospitalization
15 (56%)
12 (22%)
4.4 (1.6 to 11.8)
0.004
Previous exposure to antimicrobial agentsd




Fluoroquinolones
8 (30%)/14 (52%)
0 (0%)/5 (9%)
―/10.6 (3.2 to 34.7)
<0.001><>
β-lactam antibiotics 24 (89%)/25 (93%) 20 (37%)/32 (59%): 14.7 (3.9 to 55.4)/8.6 (1.8 to 40) <0.001>

aCI, confidence interval; COPD, chronic obstructive pulmonary disease; LRSP, levofloxacin-resistant S. pneumoniae (73).
bMedian (interquartile range).
cColonization in 3 patients.
dExposure to antimicrobial therapy during the 6 weeks prior to hospitalization/12 months before hospitalization.

Main Article

TOP